James Catto is Professor of Urology at the University of Sheffield and an Honorary Senior Clinical Research fellow at the University of Oxford.
He qualified from Leeds University in 1994 and trained in York and Sheffield, UK before a fellowship in Brisbane, Australia. He was appointed an Honorary Consultant Urological Surgeon in 2007 and specializes in Uro-Oncology. He obtained a PhD in 2004 and now runs a research group investigating the biology of urological cancers.
He was awarded the European Association of Urology thesis prize and the Bard medal from BAUS for his PhD studies. In 2007 he visited Johns Hopkins Medical School, The University of Chicago, Loyola University and The University of California, San Francisco as an EAU-AUA exchange fellow. His current research is funded by a Clinician Scientist fellowship, the MRC, The Urological Foundation and Yorkshire Cancer Research. In 2010, he was awarded the Crystal Matula by the EAU and the Astellas Education Foundation award in 2011.
He is a member of the Scientific Congress Office for the EAU. James has raised over £8.7 million in peer reviewed funding and published more than 50 primary research manuscripts.
Declaration of Interests
Research funding: James Catto has received peer reviewed funding from the NIHR, MRC, Wellcome trust, Yorkshire Cancer Research, Cancer Research UK, The European Union, The Urological Foundation, Astellas Europe Foundation and a GlaxoSmithKline Clinician Scientist Award.
Stock holdings: James Catto holds no stock in medical equipment or pharmaceutical companies.
Advisory boards: James Catto has served on advisory boards for Orion Pharmaceuticals (2013), Astellas (2012), Abbott (2015), Steba Biotech (2018), Ferring (2019), Janssen (2019) and AztraZeneca (2016, 2018 and 2019).
Lecture fees: James Catto has been paid to lecture by GlaxoSmithKline (2010), AztraZeneca (2013 and 2018), Nucleix (2018), Roche Products Limited (2017 and 2019) and Merck Sharp & Dohme Ltd (2018).
Employment or Consultancy: James Catto is serving as a consultant for AztraZeneca and Janssen, is a member of the NICE Centre for Clinical Practice and so is Expert Adviser to NICE appraisals, and is a Trustee of Fight Bladder Cancer.